The pathogenic tau protein and the -amyloid (A) cascade are among those that have been intensively studied; however, recent findings suggest that the latter is more likely to be the focus of treatment for AD [75], given that tau proteins are degraded by the peptide-based PROTAC TH006 [60]. Here, MAPT is linked to Alzheimer disease.